Abstract 452P
Background
Cancer is the leading cause of death worldwide. In 2012, around 8,2 million deaths were caused by cancer.1 Chemotherapy in cancer patients is often accompanied by bone marrow aplasia which manifests as anemia. The choice of therapy for anemia in cancer patients are blood transfusions. In addition, an Erythropoiesis-Stimulating Agent (ESA) can be added which can increase the production of erythrocytes in the bone marrow.17,18 Increased erythropoeisis process induced by ESA will bind to Erythropoietin Receptor (EpoR) on the erythropoetic cell surface in the bone marrow. In other hand, ESA therapy were still not giving a satisfied result and still lack of data about expression of EpoR. Absolute reticulocyte count (ARC) is a marker of erythrocyte production that is more accurate in distinguishing hypo or hyperproliferative anemia.
Methods
This study was an observational analytic, cross sectional study carried out at the hematology specialty clinic, integrated oncology unit, Department of Internal Medicine, Dr. M. Djamil Padang Hospital for 6 months. A sample of 30 patients who met the inclusion and exclusion criteria. Initial screening for potential subjects was carried out, the research protocol was explained and informed consent was requested.
Results
There is a decrease of EpoR expression (8481,33±5364,46 copies/uL) compared to normal value (34-3000 x 103 copies/uL). There is also a decrease of ARC (27,97±9,24 x109/L) compared to normal value (50-100 x109/L). Positive correlation was found between EpoR expression and ARC. In the statistical test using the Pearson test it was found that the correlation was significant (p < 0.05) with very strong gradations (r = 0.819).
Conclusions
There is a decrease the average of EpoR expression in patient with anemia related chemotherapy and significant positive correlation with a very strong gradation between EpoR expression and ACR .
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Division of Hematology and Medical Oncology, Internal Medicine Department, Dr. M. Djamil General Hospital, Padang, Indonesia.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract